ClinicalTrials.gov and DrugsFDA: A Comparison of Results Reporting for New Drug Approval Trials
Background: Pharmaceutical companies and other trial sponsors must submit certain trial results to ClinicalTrials.gov. The validity of these results is unclear. Purpose: To validate results posted on ClinicalTrials.gov against publicly available U.S. Food and Drug Administration (FDA) reviews on DrugsFDA. Data Sources: ClinicalTrials.gov (registry and results database) and Drugs@FDA (medical and statistical reviews). Study Selection: 100 parallel-group, randomized trials for new drug approvals (January 2013 to July 2014) with results posted on ClinicalTrials.gov (15 March 2015). Data Extraction: 2 assessors extracted, and another verified, the trial design, primary and secondary outcomes, adverse events, and deaths. Results: Most trials were phase 3 (90%), double-blind (92%), and placebo-controlled (73%) and involved 32 drugs from 24 companies. Of 137 primary outcomes identified from ClinicalTrials.gov, 134 (98%) had corresponding data at Drugs@FDA, 130 (95%) had concordant definitions, and 107 (78%) had concordant results. Most differences were nominal (that is, relative difference <10%). Primary outcome results in 14 trials could not be validated. Of 1927 secondary outcomes from ClinicalTrials.gov, Drugs@FDA mentioned 1061 (55%) and included results data for 367 (19%). Of 96 trials with 1 or more serious adverse events in either source, 14 could be compared and 7 had discordant numbers of persons experiencing the adverse events. Of 62 trials with 1 or more deaths in either source, 25 could be compared and 17 were discordant. Limitation: Unknown generalizability to uncontrolled or crossover trial results. Conclusion: Primary outcome definitions and results were largely concordant between ClinicalTrials.gov and Drugs@FDA. Half the secondary outcomes, as well as serious events and deaths, could not be validated because Drugs@FDA includes only "key outcomes" for regulatory decision making and frequently includes only adverse event results aggregated across multiple trials. Primary Funding Source: National Library of Medicine. doi: 10.7326/M15-2658.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2016 |
---|---|
Erschienen: |
2016 |
Enthalten in: |
Zur Gesamtaufnahme - volume:165 |
---|---|
Enthalten in: |
Annals of internal medicine - 165(2016), 6, Seite 421 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Schwartz, Lisa M [VerfasserIn] |
---|
Links: |
---|
BKL: | |
---|---|
Themen: |
Clinical trials |
RVK: |
---|
doi: |
10.7326/M15-2658 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC1983742120 |
---|
LEADER | 01000caa a2200265 4500 | ||
---|---|---|---|
001 | OLC1983742120 | ||
003 | DE-627 | ||
005 | 20240308191529.0 | ||
007 | tu | ||
008 | 161013s2016 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.7326/M15-2658 |2 doi | |
028 | 5 | 2 | |a PQ20161012 |
035 | |a (DE-627)OLC1983742120 | ||
035 | |a (DE-599)GBVOLC1983742120 | ||
035 | |a (PRQ)c1155-de354d4d8afced56cc820a8b268e403d769ed89fc9983808fc20dfdf726550da0 | ||
035 | |a (KEY)0583179220160000165000600421fdaacomparisonofresultsreportingfornewdrugapproval | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q DNB |
082 | 0 | 4 | |a 610 |q VZ |
082 | 0 | 4 | |a 610 |q VZ |
084 | |a XA 23600 |q AVZ |2 rvk | ||
084 | |a XA 10000 |a XA 10000 |q VZ |2 rvk |0 (DE-625)rvk/152411: | ||
084 | |a 44.61 |2 bkl | ||
084 | |a 44.00 |2 bkl | ||
100 | 1 | |a Schwartz, Lisa M |e verfasserin |4 aut | |
245 | 1 | 0 | |a ClinicalTrials.gov and DrugsFDA: A Comparison of Results Reporting for New Drug Approval Trials |
264 | 1 | |c 2016 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
520 | |a Background: Pharmaceutical companies and other trial sponsors must submit certain trial results to ClinicalTrials.gov. The validity of these results is unclear. Purpose: To validate results posted on ClinicalTrials.gov against publicly available U.S. Food and Drug Administration (FDA) reviews on DrugsFDA. Data Sources: ClinicalTrials.gov (registry and results database) and Drugs@FDA (medical and statistical reviews). Study Selection: 100 parallel-group, randomized trials for new drug approvals (January 2013 to July 2014) with results posted on ClinicalTrials.gov (15 March 2015). Data Extraction: 2 assessors extracted, and another verified, the trial design, primary and secondary outcomes, adverse events, and deaths. Results: Most trials were phase 3 (90%), double-blind (92%), and placebo-controlled (73%) and involved 32 drugs from 24 companies. Of 137 primary outcomes identified from ClinicalTrials.gov, 134 (98%) had corresponding data at Drugs@FDA, 130 (95%) had concordant definitions, and 107 (78%) had concordant results. Most differences were nominal (that is, relative difference <10%). Primary outcome results in 14 trials could not be validated. Of 1927 secondary outcomes from ClinicalTrials.gov, Drugs@FDA mentioned 1061 (55%) and included results data for 367 (19%). Of 96 trials with 1 or more serious adverse events in either source, 14 could be compared and 7 had discordant numbers of persons experiencing the adverse events. Of 62 trials with 1 or more deaths in either source, 25 could be compared and 17 were discordant. Limitation: Unknown generalizability to uncontrolled or crossover trial results. Conclusion: Primary outcome definitions and results were largely concordant between ClinicalTrials.gov and Drugs@FDA. Half the secondary outcomes, as well as serious events and deaths, could not be validated because Drugs@FDA includes only "key outcomes" for regulatory decision making and frequently includes only adverse event results aggregated across multiple trials. Primary Funding Source: National Library of Medicine. doi: 10.7326/M15-2658 | ||
540 | |a Nutzungsrecht: © COPYRIGHT 2016 American College of Physicians | ||
650 | 4 | |a Comparative analysis | |
650 | 4 | |a Pharmaceutical industry | |
650 | 4 | |a Clinical trials | |
650 | 4 | |a Drugs | |
650 | 4 | |a FDA approval | |
650 | 4 | |a Pharmaceuticals | |
650 | 4 | |a Validity | |
700 | 1 | |a Woloshin, Steven |4 oth | |
700 | 1 | |a Zheng, Eugene |4 oth | |
700 | 1 | |a Tse, Tony |4 oth | |
700 | 1 | |a Zarin, Deborah A |4 oth | |
773 | 0 | 8 | |i Enthalten in |t Annals of internal medicine |d Philadelphia, Pa. : American College of Physicians, 1927 |g 165(2016), 6, Seite 421 |w (DE-627)129060534 |w (DE-600)336-0 |w (DE-576)014391236 |x 0003-4819 |7 nnns |
773 | 1 | 8 | |g volume:165 |g year:2016 |g number:6 |g pages:421 |
856 | 4 | 1 | |u http://dx.doi.org/10.7326/M15-2658 |3 Volltext |
856 | 4 | 2 | |u http://search.proquest.com/docview/1822936965 |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4219 | ||
912 | |a GBV_ILN_4256 | ||
936 | r | v | |a XA 23600 |
936 | r | v | |a XA 10000 |b Medizinische Zeitschriften |k Medizin |k Medizin |k Medizinische Zeitschriften |0 (DE-625)rvk/152411: |0 (DE-576)206747985 |
936 | b | k | |a 44.61 |j Innere Medizin |j Innere Medizin |q VZ |
936 | b | k | |a 44.00 |j Medizin: Allgemeines |j Medizin: Allgemeines |q VZ |
951 | |a AR | ||
952 | |d 165 |j 2016 |e 6 |h 421 |